Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Account Payables (2016 - 2025)

Ocular Therapeutix has reported Change in Account Payables over the past 13 years, most recently at -$1.4 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$1.4 million for Q4 2025, down 1308.04% from a year ago — trailing twelve months through Dec 2025 was -$887000.0 (down 178.93% YoY), and the annual figure for FY2025 was -$887000.0, down 178.93%.
  • Change in Account Payables for Q4 2025 was -$1.4 million at Ocular Therapeutix, down from -$1.3 million in the prior quarter.
  • Over the last five years, Change in Account Payables for OCUL hit a ceiling of $1.7 million in Q2 2025 and a floor of -$2.4 million in Q2 2024.
  • Median Change in Account Payables over the past 5 years was $211000.0 (2021), compared with a mean of $27650.0.
  • Biggest five-year swings in Change in Account Payables: surged 745.34% in 2021 and later plummeted 1308.04% in 2025.
  • Ocular Therapeutix's Change in Account Payables stood at $366000.0 in 2021, then crashed by 406.56% to -$1.1 million in 2022, then soared by 158.47% to $656000.0 in 2023, then plummeted by 82.93% to $112000.0 in 2024, then plummeted by 1308.04% to -$1.4 million in 2025.
  • The last three reported values for Change in Account Payables were -$1.4 million (Q4 2025), -$1.3 million (Q3 2025), and $1.7 million (Q2 2025) per Business Quant data.